Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort

韩国人群中眼肌型和全身型重症肌无力的比较研究

阅读:1

Abstract

PURPOSE: To compare ocular myasthenia gravis (OMG) and generalized myasthenia gravis (GMG) in a South Korean cohort through an integrated analysis of clinical characteristics, diagnostic findings, and treatment patterns. METHODS: We conducted a retrospective study of 138 patients with myasthenia gravis (98 with OMG and 40 with GMG). Demographic characteristics, ophthalmic symptoms, serologic results, repetitive nerve stimulation test (RNST) findings, thymic pathology, autoimmune comorbidities, and treatment patterns were evaluated. RESULTS: GMG patients had a younger age at symptom onset and a higher proportion of females compared with OMG patients. Combined horizontal and vertical diplopia was more frequent in OMG. AChR antibody positivity was significantly higher in GMG than in OMG (92.5% vs. 36.3%), as were abnormal RNST findings (90.0% vs. 23.5%). A modest but statistically significant positive correlation was observed between AChR-Ab titer and the highest CMAP decrement in the overall cohort (r = 0.381, p = 0.011); however, this association was not significant when analyzed separately in OMG and GMG patients. Thymic abnormalities, particularly thymoma, were more common in GMG. Nonsteroidal immunosuppressant use-especially tacrolimus and azathioprine-was significantly more frequent in GMG, whereas corticosteroid use did not differ significantly between subtypes. Among OMG patients, systemic immunotherapy was more frequently administered to those presenting with both ptosis and diplopia than to those with isolated ptosis. CONCLUSIONS: In this South Korean cohort, OMG and GMG exhibited distinct demographic, serologic, electrophysiologic, and therapeutic profiles. Recognition of these subtype-specific differences may facilitate accurate diagnosis, individualized treatment selection, and improved clinical management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。